Seroquel's First- and Second-Line Patient Share Has Grown Since Last Year's Analysis of Prescribing Trends in Bipolar Disorder
Posted on: Monday, 22 June 2009, 10:00 CDT
Although Risperidone Is Now Available In Generics, There Is No Clear Evidence of Expanded Uptake in Early Lines of Therapy, According to a New Report from Decision Resources
Patient-Flow Forecasts Need to Take Into Account Shifts in Seroquel XR's Use by Line of Therapy Over the Next Two Years
Although surveyed psychiatrists rate the overall attributes of Abilify higher than Seroquel/Seroquel XR, surveyed primary care physicians' assessment of these two agents is the opposite. Despite the advantage that surveyed psychiatrists give to Abilify over Seroquel on side-effect and safety attributes, Abilify's patient share is second to that of Seroquel in both first- and second-line therapy.
The new report entitled Treatment Algorithms in Bipolar Disorder also finds that although risperidone is now available in generics there is no clear evidence of its expanded uptake in early lines of therapy. Approximately 15 percent of surveyed physicians do not prescribe generic risperidone first-line and only one-third of surveyed physicians estimate that they prescribe generic risperidone first-line to more than half of their bipolar patients.
By pairing patient-level claims data with primary survey data, this report can be used to build patient-flow models and analyze the assumptions driving these models.
"Our analysis of patient-flow to Seroquel XR shows that 30 percent of the patients who take it after another agent previously received Seroquel, indicating that Seroquel XR continues to garner a major portion of its business in patients using it as a replacement for Seroquel. However, approximately one-third of surveyed physicians plan to use Seroquel XR more often in the first-line over the next two years, which suggests that competitors will need to position themselves to combat Seroquel XR's growing use as a first-line treatment," stated
About Treatment Algorithm Insight Series
Decision Resources combines in-depth primary research with the most extensive claims-based longitudinal patient-level data from IMS Lifelink: Health Plans Claims database to provide exceptional insight into physicians' prescribing trends and the factors that drive therapy product choice, from diagnosis through multiple courses of treatment, for a specific disease.
About Decision Resources
Decision Resources (www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.
All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact:
Gisselle Morales Elizabeth Marshall Decision Resources Decision Resources, Inc. 781-296-2691 781-296-2563 gmorales@dresources.com emarshall@dresources.comSOURCE Decision Resources
Source: PR Newswire
Related Articles
- For Treatment of Dyslipidemia, Surveyed Physicians are Increasingly Switching Patients to a More Potent Statin Following the ENHANCE and SEAS Trials
- Teva's Azilect Use Dramatically Increases in Second-Line Therapy for the Treatment of Parkinson's Disease
- Rheumatologists Anticipate Using Orencia and Rituxan More Frequently in First- and Second-Line Therapy for the Treatment of Rheumatoid Arthritis
- Despite Availability of Numerous Generic Antidepressants, Forest Laboratories' Lexapro Retains Leadership Among First-Line Therapies in the Treatment of Major Depression
- Teva Pharmaceutical's Altered Peptide Ligand Copaxone Boasts the Greatest Patient Share Among First- and Second-Line Therapies for the Treatment of Multiple Sclerosis
- Forest Laboratories' Lexapro and Pfizer's Prozac Lead First-Line Therapy in the Treatment for Major Depression
- GlaxoSmithKline's Coreg Will Be Prescribed More and More As a First Line Therapy for the Treatment of Chronic Heart Failure As Physicians' Comfort Level With the Drug Increases
- ENTOCORT(R) EC (Budesonide) Capsules Recommended By the American Gastroenterology Association As First-Line Therapy for the Treatment of Mild-to-Moderate Crohn's Disease
- Statins Account for 81% of First-Line Therapies for Dyslipidemia Treatment
- Nearly 70% of Patients Who Take a First-Line Therapy for the Treatment of Schizophrenia Will Progress to a Second-Line Therapy Within 360 Days After Diagnosis
 |
 |
User Comments (0)
RSS Feeds